Comparison of the duration of antimicrobial activity of 2 different antimicrobial central venous catheters

Infection Control and Hospital Epidemiology

Volumn 31, Issue 3, 2010, Pages 295-297

  Matheos, Theofilos ^a   Matthias Walz, J ^a   Adams, Janice P ^a   Johnson, Karen ^a   Longtine, Karen ^a   Longtine, Jaclyn ^a   O'Neill, Melissa ^a   Heard, Stephen O ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CARBON; MINOCYCLINE; PLATINUM; RIFAMPICIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM CULTURE; BLOODSTREAM INFECTION; CENTRAL VENOUS CATHETER; CONTROLLED STUDY; ENTEROCOCCUS FAECALIS; HUMAN; INTENSIVE CARE UNIT; NONHUMAN; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

ANTI-INFECTIVE AGENTS; BACTERIAL ADHESION; CATHETERIZATION, CENTRAL VENOUS; CATHETERS, INDWELLING; GRAM-POSITIVE BACTERIA; MASSACHUSETTS; MINOCYCLINE; RIFAMPIN;

EID: 77249150437     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/650757     Document Type: Article

References (10)

1. Mermel LA. Prevention of intravascular catheter-related infections (published correction appears in Ann Intern Med 2000;133:395). Ann Intern Med 2000;132:391-402.
2. Darouiche RO, Raad II, Heard SO, et al. A comparison of two antimicrobialimpregnated central venous catheters. Catheter Study Group. N Engl J Med 1999;340:1-8.
3. Maki DG, Stolz SM, Wheeler S, Mermel LA. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter: a randomized, controlled trial. Ann Intern Med 1997;127: 257-266.
4. Fraenkel D, Rickard C, Thomas P, Faoagali J, George N, Ware R. A prospective, randomized trial of rifampicin-minocycline-coated and silverplatinum-carbon-impregnated central venous catheters. Crit Care Med 2006;34:668-675.
5. Marik PE, Abraham G, Careau P, Varon J, Fromm RE Jr. The ex vivo antimicrobial activity and colonization rate of two antimicrobial-bonded central venous catheters. Crit Care Med 1999;27:1128-1131.
6. Bassetti S, Hu J, D'Agostino RB Jr, Sherertz RJ. In vitro zones of inhibition of coated vascular catheters predict efficacy in preventing catheter infection with Staphylococcus aureus in vivo. Eur J Clin Microbiol Infect Dis 2000;19:612-617.
7. Raad I, Darouiche R, Hachem R, Mansouri M, Bodey GP. The broadspectrum activity and efficacy of catheters coated with minocycline and rifampin. J Infect Dis 1996;173:418-424.
8. Hanna H, Bahna P, Reitzel R, et al. Comparative in vitro efficacies and antimicrobial durabilities of novel antimicrobial central venous catheters. Antimicrob Agents Chemother 2006;50:3283-3288.
9. Yorganci K, Krepel C, Weigelt JA, Edmiston CE. In vitro evaluation of the antibacterial activity of three different central venous catheters against gram-positive bacteria. Eur J Clin Microbiol Infect Dis 2002;21:379-384.
10. Quinn MT, Milder FL. The Science of Oligon. http://ht.edwards.com/ resourcegallery/products/centralvenousaccess/pdfs/scienceofoligon1124.pdf. Irvine, CA: Edwards Lifesciences; 2002. Accessed August 25, 2009.